
The FDA has rejected a submission from Phoenix Biotechnology to market oleandrin as a dietary supplement. Phoenix Biotechnology submitted oleandrin …
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns

